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Abstract
Background: Prior studies have found that patients taking single-pill amlodipine/atorvastatin (SPAA) have greater 
likelihood of adherence at 6 months than those taking 2-pill calcium-channel blocker and statin combinations (CCB/
statin). This study examines whether this adherence benefit results in fewer cardiovascular (CV) events.
Methods: A retrospective cohort study was conducted using administrative claims data from the IMS LifeLink: US 
Health Plan Claims database, identifying adults already taking CCB or statin (but not both) who had an index event of 
either initiating treatment with SPAA or adding CCB to statin (or vice versa) between April 1, 2004 to August 31, 2005. 
Inclusion criteria included age 18+ years, continuously enrolled for minimum of 6 months prior and 18 months 
following treatment initiation, >1 diagnosis of hypertension, and no prescription claims for SPAA or added CCB or statin 
for 6 months prior. Exclusion criteria included >1 claim with missing or invalid days supplied, age 65+ years and not 
enrolled in Medicare Advantage, or history of prior CV events, cancer diagnosis, or chronic renal failure. The primary 
outcome measure was the rate of CV events (myocardial infarction, heart failure, angina, other ischemic heart disease, 
stroke, peripheral vascular disease, or revascularization procedure) from 6 to 18 months following index date, analyzed 
at three levels: 1) all adherent vs. non-adherent patients, 2) SPAA vs. dual-pill patients (regardless of adherence level), 
and 3) adherent SPAA, adherent dual-pill, and non-adherent SPAA patients vs. non-adherent dual-pill patients.
Results: Of 1,537 SPAA patients, 56.5% were adherent at 6 months, compared with 21.4% of the 17,910 CCB/statin 
patients (p < 0.001). Logistic regression found SPAA patients more likely to be adherent (OR = 4.7, p < 0.001) than CCB/
statin patients. In Cox proportional hazards models, being adherent to either regimen was associated with significantly 
lower risk of CV event (HR = 0.77, p = 0.003). A similar effect was seen for SPAA vs. CCB/statin patients (HR = 0.68, p = 
0.02). In a combined model, the risk of CV events was significantly lower for adherent CCB/statin patients (HR = 0.79, p 
= 0.01) and adherent SPAA patients (HR = 0.61, p = 0.03) compared to non-adherent CCB/statin patients.
Conclusions: Patients receiving SPAA rather than a 2-pill CCB/statin regimen are more likely to be adherent. In turn, 
adherence to CCB and statin medications is associated with lower risk of CV events in primary prevention patients.
Background
CVD is the number one cause of death globally and will
remain so, taking an estimated 20 million lives annually
by 2015 [1]. Two of the most prevalent and modifiable
risk factors for CVD -- hypertension and dyslipidemia --
commonly coexist. The risk of CVD is greater in people
with both of these risk factors than it is in those with
either condition alone [2,3]. Effective treatment of these
two CVD risk factors is widely available and has been
proven to reduce CV events. The benefits of antihyper-
tensive medications and 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors (statins) for reducing
CHD and stroke risk in patients at a high risk of CHD
have been demonstrated in several well-known clinical
trials [4,5]. Also, meta-analyses have shown the consis-
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tent effects from antihypertensive [6] and statin [7-9]
medications in reducing CV events. Despite these effec-
tive treatments for hypertension and dyslipidemia, and
the associated reduction in CV events, control of these
conditions often remains suboptimal, partly due to poor
patient adherence [10].
Recent analyses report that fixed dose combination
(FDC) therapy for hypertension and dyslipidemia is asso-
ciated with a greater likelihood of adherence than the his-
toric approach of prescribing medication for each risk
factor separately [10,11]. For example, patients taking sin-
gle-pill amlodipine/atorvastatin (SPAA) have a greater
likelihood of adherence at 6 months than those taking 2-
pill calcium-channel blocker and statin combinations
(CCB/statin) [10]. Other studies show that when two-pill
CCB/statin regimens are initiated close together in time,
adherence is greater than when therapy is initiated
sequentially, [12-14] and that, in general, adherence is
better with single-pill regimens vs. 2-pill regimens
[15,16]. The reasons for better adherence with FDC ther-
apy for hypertension and dyslipidemia may include
reduced pill burden [17] and reduced patient-borne med-
ication costs [18,19].
Efforts to improve patient adherence to CVD medica-
tion therapy are important, as retrospective analyses have
shown that adherence to statins and to antihypertensive
medications have been associated with reduced rates of
CV events [20-23]. In a recent review of the literature,
poor compliance with lipid-lowering treatment has been
shown to be associated with poorer clinical outcomes and
increased cardiovascular morbidity and mortality [20].
Bouchard et al. [21], using a nested case-control design,
found that adherence to statins that exceeded 90% was
associated with a significant reduction in nonfatal CAD
events after one year of treatment. Another nested case-
control analysis, by Perreault et al. [22], found that high
adherence levels to antihypertensive therapy were associ-
ated with relative risk reduction in CAD events compared
to low levels of adherence. Mazzaglia et al. [23] reported a
similar finding among newly diagnosed hypertensive
patients in a retrospective cohort analysis. To build upon
the growing body of evidence supporting the impact of
adherence on reduction in CV events, this study exam-
ines whether the adherence benefit previously demon-
strated with SPAA results in fewer CV events than for
patients on 2-pill regimens.
Methods
We conducted a retrospective cohort study using admin-
istrative claims that include medical and pharmacy data
from the IMS LifeLink: US Health Plan Claims database
for October 1, 2003 through August 31, 2006. The data-
base is comprised of fully adjudicated medical & pharma-
ceutical claims for over 65 million unique patients from
over 90 health plans across the US (with approximately 16
million covered lives per year). It includes both inpatient
and outpatient diagnoses and procedures as well as pre-
scription records, and is generally representative of the
national, commercially-insured population in terms of
age, gender, and type of health plan. The data is longitudi-
nal, with average member enrollment duration of nearly
two years. Only health plans that submit data for all
members are included in the database, ensuring complete
data capture & representative samples. The data are sub-
jected to a series of quality checks to ensure standardized
format & minimal error rates.
Study population
We identified adults taking CCB or statin (but not both)
who then initiated treatment with SPAA or added CCB to
statin (or vice versa) from April 1, 2004 to August 31,
2005. Inclusion criteria included age ≥18 years, at least
one prescription for SPAA or CCB + statin (with first pre-
scription for SPAA or the added CCB or statin in the
study period considered the index date), continuously
enrolled for minimum of 6 months prior to and 18
months following index date, >1 diagnosis of hyperten-
sion prior to or on the index date, and no claims for the
index prescription(s) for 6 months prior to index date.
Exclusion criteria included at least one prescription claim
with missing or invalid days supplied, age 65 years or
greater and not enrolled in Medicare Advantage, or his-
tory of prior CV events, cancer diagnosis, or chronic
renal failure. Patients were considered secondary preven-
tion patients if they had evidence during the pre-index
period of any of the specified CV-related events or proce-
dures, and were excluded from analysis. Otherwise,
patients' treatment was considered to be for primary pre-
vention.
This study included 3 time periods, as illustrated in Fig-
ure 1:
1. Pre-index: 6-month period in which patients were 
taking either statin or CCB
2. Adherence measurement period: 6-month period 
following initiation of SPAA or dual therapy (index) 
where adherence is assessed
3. Follow-up period: ≥12 months in which CV events 
are tabulated
Adherence
The proportion of days covered (PDC) for each of the two
drug cohorts was calculated for the 6-month adherence
measurement period. Adherence was capped at 100%,
and calculated as the total days supplied of index drug
divided by the number of days in the follow-up period (a
denominator of 180 days). Claims extending beyond day
179 were pro-rated to include only the portion of days'
supply captured within the observation period. Addition-Chapman et al. BMC Cardiovascular Disorders 2010, 10:29
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ally, if a patient refilled a prescription early, any days with
overlapping prescriptions were counted only once.
Advantages of using PDC as an adherence measure are
that it simultaneously reflects both compliance and per-
sistence, [24,25] and is a commonly used measure in
adherence studies [12,26-30], allowing useful compari-
sons of adherence levels across studies.
For this analysis, patients were considered "adherent" if
PDC by SPAA or CCB and statin was ≥80%, and non-
adherent if PDC <80% for the 6-month period. Unad-
justed adherence rates of patients in the two treatment
groups are reported for the 6-month follow-up period.
Multivariable logistic regression models with adherence
status (</≥80% PDC) as the dependent variable were also
run.
Study Outcomes
The primary outcome of interest was the rate of CV
events, as well as its relationship to 6-month adherence
levels. CV events were defined as hospitalization for
myocardial infarction (MI), heart failure, angina, other
ischemic heart disease, stroke, peripheral vascular dis-
ease, or CV revascularization procedure. CV event defi-
nition included events with either a primary discharge
diagnosis of interest or a procedure of interest using only
inpatient claims; outpatient claims were not considered.
To allow sufficient time for events of interest to occur,
this analysis was restricted to patients with at least 18
months of continuous enrollment following their medica-
tion-based index date.
Rates of CV events were analyzed at three levels:
1) all adherent patients vs. all non-adherent patients;
2) SPAA patients vs. dual-pill patients (regardless of 
adherence level);
3) adherent SPAA patients, adherent dual-pill 
patients, and non-adherent SPAA patients vs. non-
adherent dual-pill patients.
All CV events were reviewed starting at 180 days post-
index (to allow a 6-month period for the establishment of
adherence) and ending with patient disenrollment or the
end of the study period. Any CV events that may have
occurred in the first 180 days post-index were ignored for
the purpose of this analysis. CV events were defined as
the presence of claims with an ICD-9 code for a relevant
diagnosis or a CPT-4 code for a procedure of interest,
which were: myocardial infarction (MI, ICD-9 410.xx,
412), other ischemic heart disease including unstable
angina (411.xx, 414.xx, 427.xx, V45.81, V45.82), stroke/
TIA (433.xx, 434.xx, 435.x, 436, 437.0, 437.1, 438),
peripheral vascular disease (440, 440.1, 443.xx), angina
with hospitalization (413.xx), coronary artery bypass
graft (CABG, CPT-4 code 33503 - 33545), carotid endart-
erectomy (35301, 35390, 35901), coronary stenting
(92980, 92981), percutaneous transluminal coronary
angioplasty (PTCA)/thrombectomy/atherectomy (92973,
92982, 92984, 92995, 92996), or percutaneous translumi-
nal pulmonary artery balloon angioplasty (92997, 92998).
Only the first CV event in the observation period per
patient was included in the analysis. The total number of
events overall and in each of the treatment groups are
reported. Additionally, the rate of CV events was calcu-
lated as the total number of events divided by the total
amount of patient-time contributed to the analysis for
each treatment group. Patient-time was allowed to vary,
with a minimum value of 360 days per patient. The crude
rates of events (total events divided by total person-days)
are reported overall and for each cohort.
In addition to the crude rates described above, the
adjusted CV event rates for all patients and by treatment
group were determined using Cox proportional hazards
models, with covariates to account for potentially con-
founding factors. The dependent variable was days to CV
event. Independent variables included all relevant demo-
graphic and clinical characteristics.
Figure 1 Illustration of the study time periods
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Table 1: Demographic and clinical characteristics of SPAA and CCB+statin primary prevention patients
SPAA CCB+Statin
Characteristic (N = 1,537) (N = 17,910) p-value
Age: (Years)
Mean 53.5 54.8 <.001
SD 7.6 8.5
Median 55 55
Age group: (n,%) <.001
<50 years 412 26.8% 4,119 23.0%
50-59 years 816 53.1% 9,636 53.8%
60+ years 309 20.1% 4,155 23.2%
Gender: (n,%)
Male 900 58.6% 9,327 52.1% <.001
Geographic Region: (n,%) <.001
Northeast 525 34.2% 4,705 26.3%
Midwest 389 25.3% 7,314 40.8%
South 595 38.7% 5,296 29.6%
West 28 1.8% 595 3.3%
Plan Type: (n,%) <.001
Health Maintenance 
Organization (HMO)
311 20.2% 6,429 35.9%
Indemnity Plan 92 6.0% 885 4.9%
Point of Service (POS) 217 14.1% 2,313 12.9%
Preferred Provider 
Organization (PPO)
884 57.5% 7,805 43.6%
Unknown 33 2.1% 478 2.7%
Payer Type: (n,%) <.001
Commercial Plan 1,462 95.1% 16,121 90.0%
Medicaid 1 0.1% 158 0.9%
Medicare Risk 26 1.7% 1,086 6.1%
Self-Insured 38 2.5% 464 2.6%
Other/Unknown 10 0.7% 81 0.5%
Charlson Comorbidity Burden:
Mean 0.4 0.5 <.001
SD 0.7 0.8
Comorbid Conditions of Interest: (n,%)
Diabetes Mellitus 363 23.6% 5,242 29.3% <.001
Dyslipidemia 1,188 77.3% 12,217 68.2% <.001
Obesity 76 4.9% 1,063 5.9% 0.112Chapman et al. BMC Cardiovascular Disorders 2010, 10:29
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Statistical analyses
Time to CV event was plotted using the Kaplan-Meier
estimator. To adjust for differences in patient characteris-
tics for each treatment group, the time to CV event was
also modeled using a Cox proportional hazards model,
with days from index date to CV event as the dependent
variable. Independent variables included therapy type
(SPAA vs. combination), adherence status, gender, age
group, geographic region, health plan type, insurance
type, related pre-index comorbidities, and number of pre-
index antihypertensive classes being taken.
Results
Patient characteristics
As shown in Figure 2, after applying our inclusion and
exclusion criteria, 19,447 patients were available for anal-
ysis; Table 1 details the demographic and clinical charac-
teristics of these patients. The mean (SD) age was 53.5
(7.6) years for SPAA patients and 54.8 (8.5) years for the
CCB+statin patients (p < 0.001). SPAA patients were
more likely to be male than CCB+statin patients (58.6%
vs. 52.1%, respectively; p < 0.001). SPAA patients were
less likely to have diabetes but more likely to have a dys-
lipidemia diagnosis than were CCB+statin patients, and
on average were taking fewer other medications pre-
index (Table 1).
Adherence
Of the 1537 SPAA patients, 56.5% were adherent (PDC
≥80%) at 6 months, compared with 21.4% of the 17,910
CCB+statin patients (Table 2). Although adherence con-
tinued to decline over time in both groups, the percent-
age of patients adherent remained significantly higher in
the SPAA group than in the CCB+statin group at 18
months (42.3% vs. 18.7%, respectively; p < 0.001). After
adjusting for patients' clinical and demographic charac-
teristics (as listed above), SPAA patients were signifi-
cantly more likely to be adherent (OR = 4.7, p < 0.001,
Table 3) than CCB/statin patients, as were patients with
dyslipidemia (OR = 1.2).
CV event rates
The crude (unadjusted) CV event rate for each patient
stratification is shown in Table 4. Non-adherent patients
and CCB/statin patients experienced higher CV event
rates than adherent and SPAA patients, respectively
(Table 4). A similar pattern was observed when time to
CV event was examined in Kaplan-Meier analyses (Figure
3).
In multivariable Cox proportional hazards models
adjusting for the independent variables listed above in
Methods, being adherent to either regimen (pooled) was
associated with significantly lower risk of CV event (HR =
0.77, p = 0.003). In a separate model that did not adjust
for adherence status, CV events were lower for SPAA
than for CCB+statin patients (HR = 0.68, p = 0.02). A
combined model compared 4 cohorts based on the com-
bination of treatment and adherence status. Using non-
adherent CCB + statin patients as the reference group,
the risk of CV events was significantly lower among
adherent CCB + statin patients (HR = 0.79, p = 0.01) and
adherent SPAA patients (HR = 0.61, p = 0.03); the risk
was similar for non-adherent SPAA patients (HR = 0.69, p
= 0.14)..
Discussion
As with prior analyses, CCB or statin patients who start
on SPAA are more likely to be adherent to antihyperten-
Peripheral Vascular Disease 35 2.3% 476 2.7% 0.371
Chronic Obstructive 
Pulmonary Disease
39 2.5% 638 3.6% 0.035
Number of Pre-Index Unique Prescriptions: <.001
1-2 252 16.4% 1,847 10.3%
3-4 392 25.5% 3,646 20.4%
5-6 310 20.2% 3,682 20.6%
7+ 583 37.9% 8,735 48.8%
Number of Pre-Index Other Antihypertensive Classes:< . 0 0 1
0 675 43.9% 6,771 37.8%
1 718 46.7% 9,237 51.6%
2 127 8.3% 1,693 9.5%
3+ 17 1.1% 209 1.2%
Table 1: Demographic and clinical characteristics of SPAA and CCB+statin primary prevention patients (Continued)Chapman et al. BMC Cardiovascular Disorders 2010, 10:29
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Figure 2 Study cohort identification procedure, with reasons for inclusion/exclusion through the selection process
Patients with a SPAA or CCB prescription claim between April 1, 2004 and 
August 31, 2005 
N=550,147 
EXCLUDED PATIENTS 
With invalid enrollment dates, age, or gender (N=8,803) 
Ages 0-17 (N=3,453) 
Ages 65+ and not Medicare Risk (N=817) 
Insufficient pre-index enrollment of <180 days (N=123,424) 
Insufficient post-index enrollment of <540 days (N=156,852) 
Missing or invalid days supplied or quantity dispensed (N=13,823) 
Patients available for analysis, by drug:  
1,537 SPAA; 17,910 CCB+statin;  
N=19,447
sive and statin therapy in the first six months than are
patients who add a CCB to statin or a statin to CCB as 2
separate pills [10,11]. As an extension of increased adher-
ence due to single pill advantages, this study found that
greater adherence to hypertension and dyslipidemia ther-
apy appears to have translated into a lower risk of CV
e v e n t s  o v e r  t i m e  c o m p a r e d  t o  n o n - a d h e r e n t  p a t i e n t s .
Slightly over 56% of the 1537 SPAA patients had at least
80% PDC adherence in the six months following initia-
tion of therapy, compared with 21% of the 17,910 patients
prescribed both a CCB and a statin. These adherence
rates are consistent with other studies of single and dual-
pill treatment of naïve patients with antihypertensive or
statin therapy. In a study by Jackson et al., [31] the effect
of additional pills was evaluated as to its impact on
patient adherence to medication, specifically measured
via the medication possession ratio (MPR). Findings from
this study suggest that an inverse relationship exists
between additional medication tablets (pills) and patient
MPR, as measured among patients receiving antihyper-
tensive therapy in a managed care setting. MPR values
were reduced from 75.4% among patients with a 2-tablet
amlodipine regimen to 60.5% among patients with a 3-
tablet amlodipine regimen. In another study with similar
adherence findings to this study, Gerbino et al. [32] also
showed a positive relationship between utilization of the
fixed dose regimen and patient adherence, with MPR-
based adherence measured at nearly 20% less among
patients with ACE inhibitors plus CCB versus patients
with a fixed dose amlodipine-benazepril.
This study demonstrates that patients' risk of cardio-
vascular events was significantly decreased among adher-
ent patients compared with non-adherent patients.
Unadjusted results found that the 12-month cardiovascu-
lar event incidence rate was only 1.88 per 100 person-
years for adherent patients compared with 2.47 per 100Chapman et al. BMC Cardiovascular Disorders 2010, 10:29
http://www.biomedcentral.com/1471-2261/10/29
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person-years in non-adherent patients. Adherence to
either of the regimens included in the study was associ-
ated with a significantly lower risk of CV event (HR =
0.77, p = 0.003) after adjusting for potentially confound-
ing baseline characteristics in multivariable Cox propor-
tional hazards models.
This association between adherence and cardiovascular
risks is in agreement with previous studies, including the
2007 study by Munger et al. [33] In this review, medica-
tion nonadherence was found to be responsible for sev-
eral adverse health and economic outcomes, including an
increased risk of death among patients with a prior myo-
cardial infarction, an estimated annual cost of $396 to
$792 million, and 33% to 66% of medication-related hos-
pital admissions. Sever et al. [34,35] found that three
years of atorvastatin therapy produced a 79% reduction in
coronary heart disease related events, from 22.8 events
per 1,000 patient years to 4.8 events per 1,000 patient
years. That study also found benefits of amlodipine and
atorvastatin in reducing nonfatal MI by 46% [hazard ratio
0.54, confidence interval (CI) 0.40-0.72, P < 0.0001],
stroke by 37% [hazard ratio 0.63, CI 0.46-0.87, P = 0.004]
and total cardiovascular events and procedures by 27%
[hazard ratio 0.73, CI 0.63-0.86, P < 0.0001].
This study has several limitations worth noting. Since
PDC calculations are based on the assumption that
Table 2: Adherence measures for SPAA and CCB+statin primary prevention patients
SPAA CCB+Statin
(N = 1,537) (N = 17,910) p-value
6 Months
Number (%) of patients with PDC ≥80% 868 56.5% 3,825 21.4% <.001
Mean PDC (SD) 0.73 (0.26) 0.49 (0.31)
Median PDC 0.83 0.50 <.001
12 Months
Number (%) of patients with PDC ≥ 80% 712 46.3% 3,529 19.7% <.001
Mean PDC (SD) 0.66 (0.30) 0.46 (0.31)
Median PDC 0.75 0.46 <.001
18 Months
Number (%) of patients with PDC ≥ 80% 650 42.3% 3,342 18.7% <.001
Mean PDC (SD) 0.62 (0.31) 0.43 (0.32)
Median PDC 0.72 0.42 <.001
Table 3: Logistic regression model of medication adherence (PDC ≥80%) at 6 months following initiation of SPAA or 
CCB+statin
95% Confidence Limits
Odds Ratio Lower Upper Chi-Square p-value
Drug Group: SPAA vs. CCB+Statin 4.70 4.22 5.23 793.06 <.001
Gender: Female vs. Male 1.21 1.13 1.30 30.59 <.001
Pre-index Comorbidity of:
Diabetes Mellitus 1.00 0.92 1.07 0.02 0.891
Dyslipidemia 1.22 1.14 1.32 27.80 <.001
Obesity 0.84 0.72 0.98 5.15 0.023
Peripheral Vascular Disease 0.75 0.59 0.94 6.26 0.012
Chronic Obstructive Pulmonary 
Disease
0.82 0.67 0.99 4.17 0.041
Number of Pre-Index Other 
Antihypertensive Classes
1.12 1.06 1.18 18.93 <.001Chapman et al. BMC Cardiovascular Disorders 2010, 10:29
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patients take all medications for which they have pre-
scriptions filled, these measures may overestimate adher-
ence. Additionally, these adherence calculations fail to
account for the possibility that patients received medica-
tions from sources other than the pharmacies included in
the database used in this study.
Because of the way adherence was calculated in this
analysis (patients had to remain on both CCB and statin
to be considered adherent), our adherence rates may
appear low relative to what has been reported in the liter-
ature. However, given that the patients in this analysis
were prescribed both drugs, we believe patients should be
considered nonadherent for the purposes of this study if
they discontinue either CCB or statin.
Adherence was measured in a time period separate and
distinct from the period during which CV events were
identified and recorded. Due to this fact, it is possible that
CV events occurred in the 6-month adherence measure-
ment period and were not accounted for in our analysis,
or that patient adherence measured prior to CV event
monitoring is not representative of refill behavior had
adherence and events been measured concurrently. To
the extent that patients' adherence to their index medica-
tions differed between the 6-month period immediately
following initiation of therapy and the minimum 12-
month subsequent period, the estimates for adherence
may vary from the time-specific values.
Cardiovascular events were identified by healthcare
claims containing specific ICD-9 diagnosis codes. Due to
the potential for unreported, misreported or miscoded
cardiovascular events, the estimates for CV event inci-
dence may overestimate or underestimate the actual
number of clinical events. Since this limitation is similar
for both cohorts, we do not expect it to bias the analysis
for or against a cohort.
Two final limitations exist relative to analysis using a
retrospective cohort design and adjudicated healthcare
claims. Findings in this study are representative only of
the U.S. commercially insured population of patients, not
the overall population of treated patients who may have
other forms of healthcare coverage (Medicaid, Medicare,
etc.) not captured through this study methodology. Addi-
tionally, factors associated with both patient adherence
and the incidence of cardiovascular events are limited
within this study to those elements available through
health plan enrollment files and insurance claims.
Unmeasured and unknown confounding factors related
to both baseline characteristics and clinical outcomes
may exist, and their effect on these results cannot be
accurately quantified.
Conclusions
Patients receiving SPAA rather than a two-pill CCB + sta-
tin regimen are more likely to be adherent. In turn,
adherence to CCB and statin medications was associated
w i t h  l o w e r  r i s k  o f  C V  e v e n t s  i n  p r i m a r y  p r e v e n t i o n
patients.
Table 4: CV events from 6 months following initiation of SPAA or CCB+statin in primary prevention patients
Overall Adherent Non-Adherent SPAA CCB+Statin
N= (19,447) (4,693) (14,754) (1,537) (17,910)
12-month Event Rate
Total Events (N) 452 88 364 19 433
Total Person-Years 19,447 4,693 14,754 1,537 17,910
Incidence Rate per 100 person-years 2.32 1.88 2.47 1.24 2.42
Overall Event Rate
Total Events (N) 818 164 654 38 780
Total Person-Years 38,074 9,139 28,935 2,734 35,340
Incidence Rate per 100 person-years 2.15 1.79 2.26 1.39 2.21
Figure 3 Kaplan-Meier analysis of days to CV event in SPAA and 
CCB/statin primary prevention patients with no history of cancer 
or chronic renal failure
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